Physician
Hematology
Dr. Robert M. Rifkin, MD
|
|
Give Review
Robert M. Rifkin, MD is an expert in the field of Hematology. He went to medical school at University of Colorado Denver School of Medicine. University of Colorado Denver School of Medicine is a one of the best medicals schools. University of Colorado Denver School of Medicine is ranked 35/8 in Research/PrimaryCare. He received awards:"Meaningful Use Stage 1 Certification". Robert Rifkin is a published doctor and has 21 publications published. The lastest was: 'Photodynamic therapy using SnET2 for basal cell nevus syndrome: a case report.'
Publications
- Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
- Change in patient-reported outcomes during the first year post-diagnosis of multiple myeloma.
- A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achiev...
- Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newl...
- Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in ...
- A randomized, multicenter, open-label comparison of the antiemetic efficacy of dolasetron versus ondansetron for the prevention of nausea and vomiting during high-dose...
- Impact of long-acting growth factors on practice dynamics and patient satisfaction.
- Percutaneous treatment of long bone nonunions: the use of autologous bone marrow and allograft bone matrix.
- Increased pulmonary toxicity results from a 1-day versus 2-day schedule of administration of high-dose melphalan.
- A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion.
- Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.
- Photodynamic therapy using SnET2 for basal cell nevus syndrome: a case report.
- Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.
- Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
- Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin''s lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
- Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow autotransplants in newly diagnosed multiple myeloma.
- Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
- High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study.
- Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Ho...
- Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
Schools
University Of Colorado
PresbyterianSt Luke39s Medical Center
University Of Arizona Health Sciences Center
Procedures Preformed
- Breast Cancer Treatment
- Cancer Counseling
- Cancer Pain Management
- Cancer Treatment
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
University of Arizona -
University of Colorado -
University of Colorado Denver School of Medicine
Hospital
-
Sky Ridge Medical Center
Drug Facts
| NPI NUMBER | 1134103476 | |
| NPPES Provider LastName | RIFKIN | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 80218 | |
| NPPES Provider State | CO | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1232.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 62.0 | |
| Percent Opioid Claims | 5.03 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134103476 |
| Last Name Of The Provider | RIFKIN |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
Dr. Keren B. Sturtz, MD |
|
Dr. Scot M. Sedlacek, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Douglas M. Reznick, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Stephen E. Howe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael T. Parra, MD |
|
Dr. Michele L. Basche, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander R. Menter, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ioana M. Hinshaw, MD
This Doctor is OpenDoctor Recommended.
|